The global pharmaceutical landscape is shifting rapidly, driven by strategic generic entries and a clear push toward high-barrier formulations. An analysis of the Abbreviated New Drug Application (ANDA) approvals from…
The U.S. Food and Drug Administration (USFDA) continued its steady pace of generic drug approvals during the first week of June 2026, granting multiple Abbreviated New Drug Application (ANDA) approvals…
Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP on 20 May 2026.…
Steranco Healthcare has received approval from the U.S. Food and Drug Administration (USFDA) for Lacosamide through the Abbreviated New Drug Application (ANDA) pathway under application number 220366. This approval marks…
On 21-May2026, Rubicon Research Limited has received approval from the U.S. Food and Drug Administration (USFDA) for its Clonazepam Tablets USP through the Abbreviated New Drug Application (ANDA) pathway under…
In the pharmaceutical industry, staying ahead of regulatory updates is a baseline requirement; translating those updates into actionable market intelligence is what drives strategic advantage.Over a brief six-day period mid-month,…
Date of Publication: 13-Mar-2026 INTELLIGENCE OVERVIEWAgency: EMAThe European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has recently concluded a safety review regarding Ixchiq, a live attenuated vaccine used to prevent…
Date of Publication: 27-Feb-2026 INTELLIGENCE OVERVIEWAgency: EMAApplicant: Sanofi Winthrop IndustrieProduct: Acoziborole WinthropThe European Medicines Agency (EMA) has highlighted a significant advancement with its update on a new single-dose oral treatment.…
Date of Publication: 19-Feb-2026 INTELLIGENCE OVERVIEWAgency: EMAThe European Medicines Agency (EMA) has published its updated pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2026. The document provides outcomes…
Date of Publication: 10-Feb-2026 INTELLIGENCE OVERVIEWAgency: EMAThe European Medicines Agency (EMA) has published the minutes of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting held on 24–27 November 2025. The document…